期刊文献+

TGF-β1的非Smad4依赖性途径与胰腺癌细胞耐药性的相关性

Relationship between Smad4-independent pathway of TGF-β1 and drug-resistance of pancreatic cancer cell line
下载PDF
导出
摘要 目的:研究TGFβ1的非Smad4依赖性途径与胰腺癌耐药性之间的相关性。方法:采用MTT法观察Smad4纯合性缺失的胰腺癌细胞株BxPC3对不同化疗药物(5Fu、健择、草酸铂、顺铂、开普拓和表柔比星)的敏感性差异;MTT法观察转染了pcDNA3TGFβ1质粒的BxPC3细胞及5ng/ml和10ng/mlTGFβ1作用后的BxPC3细胞对顺铂敏感性的影响、蛋白免疫印迹检测TGFβ1作用后p170的改变情况。结果:BxPC3细胞对健择和表柔比星的敏感性最差,5Fu、开普拓和草酸铂次之,顺铂作用最强。转染了TGFβ1全长cDNA质粒的BxPC3细胞对顺铂的耐受能力增强;给予TGFβ1细胞外刺激后,也能增加细胞对顺铂的耐受能力。蛋白免疫印迹表明TGFβ1能增加p170(mdr1)的表达。结论:TGFβ1的非Smad4依赖性途径能通过上调p170的表达而增加肿瘤细胞的耐药性。 Objective.. To investigate ,he relationship between the Smad4-independent pathway of TGF-β1 and drug-resistance of pancreatic cancer. Methods: The sensitivities of Smad4 homozygous-deleted pancreatic cancer cell line BxPC3 to different kinds of anti-cancer drugs (5-Fu. Gemzar. Oxaliplatin, Cisplatin, CPT-11 and Epirubicin) were observed by MTT assay before and after they were transfected with full-length eDNA of TGF-β1 or treated with TGF-β1 (5 and 10 ng/ml) solution. Western blot was used to detect p170 protein expression after stimulation with different concentrations of TGF-β1. Results: Cisplatin had the most powerful killing effect on BxPC3 cells, followed by Oxaliplatin, 5-Fu and CPT-11 with moderate effect and Gemzar and Epirubicin with the least effect. Cells transfected with full-length eDNA of TGF-β1 or treated with TGF-β1 solution became less sensitive to Cisplatin. Western blot revealed upregulation of p170 expression by TGF-β1. Conclusion: The Smad4-independent pathway of TGF-β1 can increase the drug resistance of pancreatic cancer cells through upregulating expression of p170.
出处 《第二军医大学学报》 CAS CSCD 北大核心 2005年第10期1103-1106,共4页 Academic Journal of Second Military Medical University
基金 长海医院新一轮学科建设计划基金(20031119)
关键词 胰腺肿瘤 药物耐受性 转化生长因子Β 非Smad4依赖性途径 pancreatic neoplasms drug tolerance transforming growth factor β Smad4-independent pathway
  • 相关文献

参考文献10

  • 1吴月兵.肿瘤细胞多药耐药的基础和临床研究进展[J].肿瘤防治研究,2003,30(3):249-251. 被引量:4
  • 2Cummings J,Zelcer N,Allen JD,et al.Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins[J]. Biochem Pharmacol,2004,67(1): 31-39.
  • 3Cummings J, Ethell BT,Jardine L,et al.Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives[J]. Cancer Res,2003, 63(23): 8443-8450.
  • 4Gorlick R, Bertino JR.Drug resistance in colon cancer[J]. Semin Oncol,1999,26(6): 606-611.
  • 5Kawai K, Sakurai M, Sakai T, et al.Demonstration of mdr 1 P-glycoprotein isoform expression in benign and malignant human prostate cells by isoform-specific monoclonal antibodies[J]. Cancer Lett,2000, 150(2): 147-153 .
  • 6Pommier Y,Sordet O,Antony S,et al. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks[J]. Oncogene,2004,23(16): 2934-2949.
  • 7Miller DW, Fontain M, Kolar C,et al.The expression of multidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines[J].Cancer Lett, 1996,107(2):301-306.
  • 8Liu B, Staren ED, Iwamura T,et al. Mechanisms of taxotere-related drug resistance in pancreatic carcinoma[J].J Surg Res,2001,99(2):179-186.
  • 9Lage H, Dietel M.Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells [J]. J Cancer Res Clin Oncol,2002,128(7): 349-357.
  • 10Tonnies H, Lage H.Chromosomal imbalances associated with drug resistance and thermoresistance in human pancreatic carcinoma cells[J]. Eur J Cell Biol, 2004, 83(10): 591-601.

二级参考文献17

  • 1高烨.高晓东.吴芳颐.蟾酥灵对HL-60/ADR耐药细胞株作用的初步研究[J].中国实验血液学杂志,2001,9:173-173.
  • 2Tai HL. Technology evaluation: Valspodar, Novartis[J]. Curt Opin Mol Ther, 2000,2(4):459-467.
  • 3Marbeuf Gueye C, Salerno M, Quidu P, et al. Inhibition of the Pglycoprotein and multidrug resistance protein - mediated efflux of anthracyclines and calceina cetoxymethyl ester by PAK-104P[J]. Eur J Pharmacol, 2000,391(3):207-216.
  • 4Motoji T, Motomura S, Wang YH. Multidrug resistance of acute leukemia and a strategy to overcome it[J].Int J Hematol, 2000, 72(4):418-424.
  • 5Swannie HC, Kaye SB. Protein kinase C inhibitors[J]. Curr Oncol Rep, 2002, 4(1):37-46.
  • 6Komuro Y, Udagawa Y, Susumu N, et al. Paclitaxel and SN-38 overcome cisplatin resistance of cell lines by down - regulating the influx and efflux system of cispaltin[J]. Cancer Res, 2001,92(11):1242-1250.
  • 7Poirson Biochat F, Concalves RA, Miceoli L, et al. The expression of drug resistance gene products during the progression of human prostate cancer[J]. Clin Cancer Res, 2000,6(2):643-653.
  • 8Mistry P, Stewart AJ, Dangerfield W, et al. In vitro and in vivo characterization of XRl1576, a novel, orally active, dual inhibitor of topoisomeraseⅠand Ⅱ[J]. Anticancer Drugs, 2002, 13(1):15-28.
  • 9Pophilic camptothecin BUP1350 is an effective drug in experimental human cancer[J].Int J Cancer, 2000,15,88(2):260-266.
  • 10Kigawa J, Sato S, Shirnada M, et al. p53 gene status and chemosensitivity in ovarian cancer[J]. Hum Cell, 2001, 14(3):165-171.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部